Figure 3.

Antitumor effect of oHSV-CD40L. (A) Experimental layout of oHSVs therapy in Pan02_HVEM model. Mice were inoculated with Pan02_HVEM cells on day 0. The treatments were performed on days 8, 11, and 14 (arrows) with PBS, oHSV, or oHSV-CD40L, respectively. (B) Tumor volumes were measured every third day and plotted as the vertical axis (n=6). (C) The survival of Pan02_HVEM-bearing mice was plotted using Kaplan-Meier analysis and log-rank test (n=6). (D) On day 20, mice were executed and Pan02_HVEM tumors were isolated from individual mice and pictured with the treatments labeled on the left. The weight of each tumor sample was presented in E (n=5). (F) Experimental layout of oHSVs therapy in subcutaneous KPC model. The treatments were performed on day 4, 7, and 10 with PBS, oHSV, or oHSV-CD40L, respectively. (G) Tumor volumes were monitored and plotted as the vertical axis (n=6). (H) The survival of KPC-bearing mice was subjected to Kaplan-Meier analysis and log-rank test (n=6). (I) On day 16, KPC tumors were isolated from individual mice and pictured. The weight of each tumor sample was presented in J (n=6). Data were presented as mean+SD (B and G) or ±SD (E and J). Two-tailed Student’s t-test was performed in B (on day 20), E, G (on day 19), and J. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. oHSV, oncolytic herpes simplex virus-1; PBS, phosphate buffered saline.